

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application:

**Listing of Claims:**

Claims 1-56. (Cancelled)

Claim 57. (Previously Presented): A method of liquefying a vitreous and/or inducing posterior vitreous detachment of an eye of a subject, comprising contacting the vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in liquefying a vitreous and/or inducing posterior vitreous detachment of the eye of a subject.

Claim 58. (Previously Presented): The method of claim 57, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin.

Claim 59. (Previously Presented): The method of claim 57, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor.

Claim 60. (Previously Presented): The method of claim 57, wherein the subject is a human.

Claim 61. (Previously Presented): The method of claim 57, wherein the method is used for treating a subject having, or at risk of developing, a vitreoretinal disease or disorder.

Claim 62. (Withdrawn): The method of claim 57, wherein the method is used to prevent a subject from developing a vitreoretinal disease or disorder.

Claim 63. (Currently Amended): The method of claim 57, wherein the method is performed in the absence of non-pharmacological vitrectomy.

Claim 64. (Previously Presented): The method of claim 57, wherein the method is performed as an adjunct to vitrectomy.

Claim 65. (Currently Amended): The method of claim 57, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye.

Claim 66. (Previously Presented): A method of treating a vitreoretinal disease or disorder, or a complication of a vitreoretinal disease or disorder, of an eye of a subject, comprising contacting a vitreous and/or an aqueous humor in the eye of the subject with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject, thereby treating the vitreoretinal disease or disorder, or the complication of the vitreoretinal disease or disorder, of the eye of the subject.

Claim 67. (Previously Presented): The method of claim 66, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin.

Claim 68. (Previously Presented): The method of claim 66, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor.

Claim 69. (Previously Presented): The method of claim 66, wherein the subject is a human.

Claim 70. (Currently Amended): The method of claim 66, wherein the method is performed in the absence of non-pharmacological vitrectomy.

Claim 71. (Previously Presented): The method of claim 66, wherein the method is performed as an adjunct to vitrectomy.

Claim 72. (Currently Amended): The method of claim 66, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye.

Claim 73. (Withdrawn): A method of preventing a vitreoretinal disease or disorder, or a complication of a vitreoretinal disease or disorder, of an eye of a subject, comprising contacting a vitreous and/or an aqueous humor with an effective amount of a composition comprising microplasmin, wherein the method results in vitreous liquefaction and/or posterior vitreous detachment in the eye of the subject, thereby preventing the vitreoretinal disease or disorder, or the complication of the vitreoretinal disease or disorder, of the eye of the subject.

Claim 74. (Withdrawn): The method of claim 73, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin.

Claim 75. (Withdrawn): The method of claim 73, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor.

Claim 76. (Withdrawn): The method of claim 73, wherein the subject is a human.

Claim 77. (Withdrawn-Currently Amended): The method of claim 73, wherein the method is performed in the absence of non-pharmacological vitrectomy.

Claim 78. (Withdrawn): The method of claim 73, wherein the method is performed as an adjunct to vitrectomy.

Claim 79. (Withdrawn-Currently Amended): The method of claim 73, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye.

Claim 80. (Previously Presented): A method of performing a vitrectomy in a subject, comprising contacting a vitreous and/or aqueous humor of an eye of the subject with an effective amount of a composition comprising microplasmin, prior to or at the same time as the removal of the vitreous.

Claim 81. (Previously Presented): The method of claim 80, wherein said microplasmin is selected from the group consisting of recombinant microplasmin, stabilized microplasmin, and stabilized, recombinant microplasmin.

Claim 82. (Previously Presented): The method of claim 80, wherein the composition is a liquid solution, and wherein the step of contacting the vitreous and/or the aqueous humor with the composition comprises injecting the liquid solution into the vitreous and/or the aqueous humor.

Claim 83. (Previously Presented): The method of claim 80, wherein the subject is a human.

Claim 84. (Currently Amended): The method of claim 80, wherein an effective amount of microplasmin is in the range of 0.005 mg to 0.2 mg per eye.